drugset / Trial / NCT00071006

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

NCT00071006

Phase 2 Completed 12 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.

Timeline

Start
2003-09
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg